Wall Street Zen upgrades Vertex Pharmaceuticals stock to Buy

Published on 10/23/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rating moved from Hold to Buy on October 17, 2026. Vertex Pharmaceuticals stock costs EUR 474.58 at Lang & Schwarz on October 23, 2026.

Ratings and upcoming dates

Wall Street Zen upgraded Vertex Pharmaceuticals from Hold to Buy on October 17, 2026.
Second-quarter 2026 revenue reached USD 3.33 billion, up 12.50 percent year over year.
Vertex Pharmaceuticals stock trades at EUR 474.58 at 11:18 a.m. CEST at Lang & Schwarz on October 23, 2026.
Third-quarter results are scheduled for November 2, 2026.

Extreme Nahaufnahme von Pharmakapseln und Tabletten auf glänzender Glasoberfläche — Vertex Pharma US92532F1003 zeigt eine Makroaufnahme von Pharma-Kapseln und Tabletten mit feinen Wassertropfen, Illustration mit AI erstellt.

Vertex Pharmaceuticals (ISIN US92532F1003) was upgraded from Hold to Buy by Wall Street Zen on October 17, 2026, while its stock stood at EUR 474.58 at Lang & Schwarz on October 23, 2026 at 11:18 a.m. CEST. The rating change gives investors a fresh reference point ahead of the company's next quarterly report, but the latest operating figures remain the stronger test of the growth story.

Why the rating matters

According to MarketBeat on October 17, 2026, Wall Street Zen moved Vertex from Hold to Buy. The same report listed 24 Buy ratings, one Strong Buy rating and three Hold ratings, with a consensus target of USD 579.81.

The counterweight is valuation discipline. Vertex reported USD 4.73 in adjusted earnings per share for the second quarter of 2026, versus USD 4.74 consensus, even as revenue exceeded the USD 3.23 billion estimate by USD 100.00 million, according to MarketBeat.

Three dated signals

On August 3, 2026, second-quarter revenue reached USD 3.33 billion, up 12.00 percent year over year, according to the Yahoo Finance transcript. On the same date, management raised full-year 2026 revenue guidance to USD 13.10 billion to USD 13.20 billion and retained a non-cystic-fibrosis revenue goal of at least USD 500.00 million.

That sequence matters because the business is still concentrated in cystic-fibrosis medicines, while newer products are adding measurable scale. In the second quarter of 2026, CASGEVY generated USD 76.00 million and JOURNAVX generated USD 50.00 million, according to the earnings-call transcript.

What does Buy mean for Vertex?

The upgrade points to confidence in the pipeline and product launches, but the figures show a company balancing revenue growth with investment. Second-quarter 2026 net income was USD 1.10 billion, while operating cash flow was USD 1.13 billion, giving the expansion plan financial support.

Upcoming milestones

MarketBeat lists November 2, 2026 as the expected date for Vertex's third-quarter results, with the call scheduled for 4:30 p.m. ET. The company also has a November 30, 2026 PDUFA date for povetacicept in IgA nephropathy, a milestone described in the earnings-call transcript.

Stock price and investor context

Vertex Pharmaceuticals stock was trading at EUR 474.58 at Lang & Schwarz on October 23, 2026 at 11:18 a.m. CEST. Its primary listing is Nasdaq, where the stock last stood at USD 535.17 on October 22, 2026 at 4:00 p.m. ET; the market capitalization was USD 135.6 billion at that point. The 52-week range was USD 403.16 to USD 560.25.

The further course of trading is shown by the continuously updated real-time quote of Vertex Pharmaceuticals stock.